Gene Therapy for Glycogen Storage Disease Type Ia: Less Cornstarch in a Phase 3 Trial

General Medical Discoveries · Human study — phase 3 / therapy approved in the United States

Glycogen storage disease type Ia is a rare genetic disorder that makes it difficult to maintain blood glucose during periods without food, so many patients need regular doses of uncooked cornstarch. In a randomised phase 3 trial, a single dose of DTX401 (pariglasgene brecaparvovec) reduced daily cornstarch intake after 48 weeks by about 41%, compared with 10% with placebo, and the trial reported that its prespecified measures of glycaemic control were maintained. The FDA review was more cautious: treated participants had numerically more hypoglycaemia and slightly more time below glucose thresholds, so reduced cornstarch use should not be interpreted as complete normalisation of glucose regulation. An orthopaedic surgeon following advances in gene therapy should note that the trial was small and that longer follow-up is still needed to understand the durability of benefit and long-term safety. The FDA granted accelerated approval in the United States on 19 August 2026 for patients aged 8 years and older, based on reduced cornstarch intake; continued approval may depend on confirmatory evidence, and regulatory status and availability may differ in Europe.

Source: Mitchell JJ, Abdenur JE, de Boer F, et al. Phase 3 Randomized Trial Results of DTX401 AAV Gene Therapy for the Treatment of GSDIa. Journal of Inherited Metabolic Disease. First published 31 August 2026. DOI: 10.1002/jimd.70241; PubMed PMID 42674977. The open-access full text and bibliographic record were checked on 15 September 2026; no correction or retraction was found in the records checked. U.S. regulatory status and additional safety context were checked against the FDA approval materials for Genglycos (pariglasgene brecaparvovec-opnr), 19 August 2026.

Polish version · Back to General Medical Discoveries

Content prepared by: Tomasz Poboży - orthopaedic surgeon.